Arno Therapeutics Inc ARNI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- — / —
- Market Cap
- $2,862.29
- Volume/Avg
- 350 / 350
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 4
- Website
- http://www.arnothera.com
Valuation
Metric
|
ARNI
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ARNI
Financial Strength
Metric
|
ARNI
|
---|---|
Quick Ratio | 1.39 |
Current Ratio | 1.52 |
Interest Coverage | −323.28 |
Quick Ratio
ARNI
Profitability
Metric
|
ARNI
|
---|---|
Return on Assets (Normalized) | −708.63% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ARNI
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wqtprgpy | Krfx | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xdwlmnr | Tchwnsc | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dvxgjxpcm | Ldjvd | $106.1 Bil | |
MRNA
| Moderna Inc | Dnbgsnkl | Mgqyb | $42.3 Bil | |
ARGX
| argenx SE ADR | Bhmfqwl | Gtxwx | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Byccfplds | Rxc | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ryvyyxm | Hzxgr | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kwltxxsl | Jqqymg | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jcnfdlbr | Rcfyds | $13.6 Bil | |
INCY
| Incyte Corp | Klrmtxtyp | Dtzgyv | $12.8 Bil |